Polyrizon

Polyrizon EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Polyrizon (PLRZ) as of Oct 21, 2026 is -1.69. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -15.17 — a change of -88.84% (higher).

EV/FCF

-1.69

YoY

-88.84%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Polyrizon is 2025 -1.69 . EV/FCF (Enterprise Value to Free Cash Flow) of Polyrizon was 2024 -15.17 . It decreases by -88.84% higher compared to the previous year.

The Polyrizon EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2020
-252.44 USD
Jan 1, 2021
-38.02 USD
Jan 1, 2022
-18.10 USD
Jan 1, 2023
-37.45 USD
Jan 1, 2024
-15.17 USD
Jan 1, 2025
-1.69 USD
The Polyrizon EV/FCF history
YEAREV/FCFYoY
-1.69-88.84%
-15.17-59.50%
-37.45+106.97%
-18.10-52.41%
-38.02-84.94%
-252.44—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Polyrizon Stock analysis

What does Polyrizon do? Polyrizon Ltd develops medical device hydrogels delivered as nasal sprays that form a thin barrier in the nasal cavity to block viruses and allergens. The company specializes in creating a biological mask using naturally occurring building blocks, focusing on both product development and commercialization. Medical specialists and researchers collaborate with Polyrizon Ltd to advance their intranasal solutions. The firm's primary revenue comes from the development and commercialization of its nasal spray hydrogel products. These products target healthcare providers and consumers seeking protection against viral and allergen exposure. By forming a shield containment barrier, Polyrizon Ltd offers a solution that complements existing health measures without requiring additional equipment. Polyrizon Ltd's business model centers on the creation of a unique nasal barrier technology. The company leverages its focus on intranasal delivery to address market needs for non-invasive protection. Its collaboration with medical specialists ensures that its products meet clinical standards and user requirements. Polyrizon is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Polyrizon stock

EV/FCF (Enterprise Value to Free Cash Flow) of Polyrizon is -1.69 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Polyrizon changed from -15.17 to -1.69, representing a -88.84% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Polyrizon since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Polyrizon with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Polyrizon

All Key Metrics — Polyrizon